Selecting the Optimal Radiation Modality in Prostate Cancer

Abstract: There are numerous radiation modalities for the definitive treatment of localized prostate cancer. Classic clinical trials have established the basic tenets of treatment approaches, and […]

New Drug Approvals in Prostate Cancer and Their Effect on the Treatment Landscape

Abstract: Prostate cancer is the most frequently diagnosed non-skin cancer and the second leading cause of cancer-related mortality in men in the United States. Over the […]

Highlights in Prostate Cancer From the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium

February 16-18, 2023 • San Francisco, California and Virtual Talazoparib Improves Radiographic Progression-Free Survival in Patients With Metastatic Castration-Resistant Prostate Cancer The addition of talazoparib (Talzenna, […]

The Addition of Darolutamide to Androgen Deprivation Therapy and Docetaxel in a 55-Year-Old Man With Metastatic Hormone-Sensitive Prostate Cancer

Case 3 of a 3-Part Series Patient Case In November 2021, a 55-year-old man presented to his primary care physician reporting difficulties with urination. The patient […]

Cases in the Management of Nonmetastatic Castration-Resistant Prostate Cancer: Darolutamide Added to Leuprolide in a 73-Year-Old Patient

Case 2 of a 3-Part Series Patient Case A 73-year-old man was diagnosed with prostate cancer based on a prostate-specific antigen (PSA) level of 6.5 ng/mL. […]

Factors That Guide Selection Among Androgen Receptor Inhibitors in Patients With Nonmetastatic Castration-Resistant Prostate Cancer

Abstract: Prostate cancer is the most common cancer affecting men in the United States. A significant proportion of men have nonmetastatic castration-resistant prostate cancer (CRPC), in which […]

Update on Metastatic Hormone-Sensitive Prostate Cancer

H&O How often do men present with de novo metastatic prostate cancer? KC In places where we do a lot of screening, such as the United […]

Highlights in Advanced Prostate Cancer From the 2022 American Society of Clinical Oncology Genitourinary Cancers Symposium

A Review of Selected Presentations From the ASCO GU Symposium • February 17-19, 2022 • San Francisco, California Exposure-Adjusted Safety Analyses of the VISION Phase 3 […]

When to Use Germline Genetic Testing in Prostate Cancer

H&O What germline DNA repair gene mutations play a role in prostate cancer? VG Many DNA repair genes play a role in hereditary prostate cancer. These […]

Cases in the Management of Nonmetastatic Castration-Resistant Prostate Cancer: Darolutamide as the First Androgen Receptor Inhibitor in a Fit, Older Man

Case 1 of a 3-Part Series Patient Case A 71-year-old man presented to his urologist reporting hematuria during the previous month. A complete blood count was […]

Combination Therapy With Radium-223 and Enzalutamide in Castration-Resistant Prostate Cancer

H&O What question was your recent study in The Oncologist designed to answer? BLM We recently published the final results of our phase 2 study, which […]

Highlights in Prostate Cancer From the 2021 European Society for Medical Oncology Congress and the 2021 American Urological Association Meeting

Objective Computerized Cognitive Assessment in Men With Metastatic Castrate-Resistant Prostate Cancer Randomly Receiving Darolutamide or Enzalutamide in the ODENZA Trial The second-generation androgen receptor inhibitor enzalutamide […]

Highlights in Advanced Prostate Cancer From the 2021 American Society of Clinical Oncology Annual Meeting

A Review of Selected Presentations From the 2021 ASCO Annual Meeting • June 4-8, 2021 Phase 3 Study of 177Lu-PSMA-617 in Patients With Metastatic Castration-Resistant […]

Highlights in Advanced Prostate Cancer From the 2021 American Society of Clinical Oncology Genitourinary Cancers Symposium

A Review of Selected Presentations From the All-Virtual Genitourinary Cancers Symposium • February 11-13, 2021 177Lu-PSMA-617 (LuPSMA) Versus Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer Progressing […]

Hem/Onc News

Selinexor Approved for Multiple Myeloma On July 3, the US Food and Drug Administration (FDA) granted accelerated approval to selinexor (Xpovio, Karyopharm) in combination with dexamethasone […]

Highlights in Advanced Prostate Cancer From the 2019 ASCO Genitourinary Cancers Symposium

A Review of Selected Presentations From the 2019 ASCO Genitourinary Cancers Symposium • February 14-16, 2019 • San Francisco, California ARAMIS: Efficacy and Safety of […]

Hem/Onc News

Ivosidenib Approved for Relapsed or Refractory Acute Myeloid Leukemia On July 20, the US Food and Drug Administration (FDA) approved ivosidenib (Tibsovo, Agios) for adults with […]

Hem/Onc News

Apalutamide Approved for Use in Nonmetastatic Castration-Resistant Prostate Cancer The US Food and Drug Administration (FDA) on February 14 approved the next-generation androgen receptor inhibitor apalutamide […]

Prognostic and Therapeutic Implications of DNA Repair Gene Mutations in Advanced Prostate Cancer

Abstract: Recent work directed toward understanding the molecular features of advanced prostate cancers has revealed a relatively high incidence of both germline and somatic alterations […]

The Role of Genomics in Patients With Advanced Prostate Cancer

H&O What are the main technologic advances that have spurred on the current interest in genomics? MH The current interest in genomics was a downstream […]